The pattern of drug resistance among newly diagnosed and old cases of pulmonary tuberculosis in NRITLD

Archives of Iranian Medicine

Volumn 6, Issue 4, 2003, Pages 255-260

  Mansoori, Seyed Davood ^a   Arami, Siamak ^a,b   Mirabolhasani, Zahra ^a   Farnia, Paria ^a   Velayati, Ali Akbar ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acquired; Drug resistance; Initial; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG EXPOSURE; HUMAN; IRAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT CODING; SPUTUM SMEAR; TUBERCULOSIS CONTROL;

EID: 1342269817     PISSN: 10292977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med. 2001; 345: 170-4.
2. Tahaoglu K, Kizkin O, karagoz T, et al. High initial and acquired drug resistance in pulmonary tuberculosis in Turkey. Tuber Lung Dis. 1994; 75: 324-8.
3. Espinal MA, Kim SJ, Suarez P, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA. 2000; 283: 2537-45.
4. Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Clin Infect Dis. 1997; 24 (Suppl 1): S121-30.
5. Pablos-Mendez A, Raviglione MC, Leszlo, et al. Global surveillance for antituberculosis drug resistance, 1994-1997. World Health Organization International Union Against Tuberculosis and Lung Disease Working Group on Antituberculosis Drug Resistance Surveillance. N Engl J Med. 1998; 338: 164-9. Erratum: N Engl J Med. 1998; 339: 139.
6. Horsburgh CR Jr, Feldman S, Ridzon R, et al. Practice guideline for the treatment of tuberculosis. Clin Infect Dis. 2000; 31: 633-9.
7. Jacobs RF. Multiple drug-resistant tuberculosis. Clin Infect Dis. 1994; 19: 1-8.
8. Veen J. Drug resistant tuberculosis: back to sanatoria, surgery, and cod-liver oil? Eur Respir J. 1995; 8: 1073-5.
9. Cole ST, Telenti A. Drug resistance in Mycobacterium tuberculosis. Eur Respir J Suppl. 1995; 20: 701-13.
10. Bradford WZ, Daley CL. Multiple drug-resistant tuberculosis. Infect Dis Clin North Am. 1998; 12: 157-72.
11. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993; 328: 527-32.
12. Martin-Casabona N, Alcaide F, Coll P, et al. Drug resistance in Mycobacterium tuberculosis. A multicenter study of the Barcelona area. Grupo de Trabajo sobre Resistencias en Tuberculosis [in Spanish]. Med Clin Barc. 2000; 115: 493-8.
13. Mansoori D, Jamaati HR, Ghazisaeedi K, et al. Multiple drug-resistant tuberculosis. Irn J Infec Dis Trop Med. 1999; 3: 39-46.
14. al-Orainey IO. Drug resistance in tuberculosis. J Chemother. 1990; 2: 147-51.
15. Abe C, Hirano K, Wada M, et al. Resistance of Mycobacterium tuberculosis to four first-line antituberculosis drugs in Japan, 1997. Int J Tuberc Lung Dis. 2001; 5: 46-52.
16. Schluger NW, Lawrence RM, McGuiness G, et al. Multidrug-resistant tuberculosis in children: two cases and a review of the literature. Pediatr Pulmonol. 1996; 21: 138-42.
17. Bass JB Jr, Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med. 1994; 149: 1359-74.
18. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis. 1986; 133: 423-30.
19. Iseman MD, Goble M. Multidrug-resistant tuberculosis. N Engl J Med. 1996; 334: 267-9.
20. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994; 330: 1179-84.
21. Zellweger JP. Drug-resistant pulmonary tuberculosis. Eur Respir J. 1995; 8: 1067.
22. Horsburgh CR Jr. The global problem of multidrug-resistant tuberculosis: the genie is out of the bottle. JAMA. 2000; 283: 2575-6.
23. Maher D, Chaulet P, Spinaci P. Treatment of tuberculosis: guidelines for national programmes. 2nd ed. Geneva : WHO; 1997: 29.
24. Albino JA, Reichman LB. The treatment of tuberculosis. Respiration. 1998; 65: 237-55.
25. Kennedy N, Billington O, Mackay A, et al. Reemergence of tuberculosis. Br Med J. 1993; 306: 514.
26. Di Perri G, Vento S, Concia E, et al. Multidrug-resistant tuberculosis. N Engl J Med. 1996, 334: 268-9.
27. Murray CJ, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention, and cost. Bull Int Union Tuberc Lung Dis. 1990; 65: 6-24.
28. Lambregts-van Weezenbeek CS. Drug-resistant Mycobacterium tuberculosis in the Netherland [in Dutch]. Ned Tijdschr Geneeskd. 1996; 140: 2187-91.
29. Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA. 1995; 273: 220-6.
30. Nardini S. The treatment of drug-resistant tuberculosis. Monaldi Arch Chest Dis. 1994; 49: 269-70.
31. World Health Organization. Communicable disease antituberculosis drug resistance in the world. Report No. 2: Prevalence and Trends WHO/CDS/TB/2000; 278.